Warning Letter Cites Philips for CT Manufacturing Site in China

Inadequate responses to the findings of an October 2023 FDA inspection of Royal Philips’ Suzhou, China, facility has earned the company a Warning Letter citing the risks of malfunctioning of cable connection failure and software defects.
Source: Drug Industry Daily